Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Inhibiting the p53-MDM2 interaction restores the function of the tumour suppressor protein, p53, and offers a promising avenue for anticancer therapies. Herein, a novel series of pyrazoline-derived compounds was developed and synthesised to serve as potential inhibitors of the p53-MDM2 interaction. Scaffold hopping was adopted via replacing the cis-imidazoline core of Nutlin-2 with a pyrazoline core, and molecular docking confirmed the binding orientation of the designed compounds at the p53-MDM2 interaction site. The antiproliferative activities of these compounds were evaluated against the NCI60 cell lines, where compounds 6c, 6d and 9d displayed the highest inhibitory activities. Subsequently, compound 6d was selected for the five-doses NCI60 cell panel assay to afford a mean GI value of 8.39 μM. Moreover, 6d significantly reduced MDM2 expression and elevated the expression of p53 in an ELISA-based assay, yielding a biochemical IC value of 13.8 μM against MDM2, which was confirmed by Western blot as well. Cytotoxicity study confirmed the selectivity of 6d towards cancerous cell lines over normal cell lines. Additionally, X-ray crystallography was used to check the stereochemistry of compound 6d. These newly identified MDM2 inhibitors represent promising candidates for the development of novel targeted anticancer agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ardp.70085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Novel Drug-Conjugate Molecule with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer.
J Med Chem
September 2025
School of Pharmacy, Second Military Medical University, Shanghai 200433, P. R. China.
The blocking interaction between p53 and its negative regulator MDM2 is an engaging therapeutic strategy for antitumor drug development, and there are several drug candidates of p53-MDM2 inhibitors in clinical trials. In the present study, novel drug conjugates of p53-MDM2 inhibitors and topoisomerase I (TOP1) inhibitors have been designed based on bioinformatics analysis results of ten tumor tissues. Among them, showed potent antiproliferative activity against three cell lines HCT116, SJSA-1, and A549, with the strongest p53-MDM2 and TOP1 inhibitory activity.
View Article and Find Full Text PDFDiscovery of Furopyrimidine-Pyrazole Hybrid Compounds Targeting p53-MDM2 Interaction as Anticancer Agents.
Arch Pharm (Weinheim)
September 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.
Inhibiting the p53-MDM2 interaction restores the function of the tumour suppressor protein, p53, and offers a promising avenue for anticancer therapies. Herein, a novel series of pyrazoline-derived compounds was developed and synthesised to serve as potential inhibitors of the p53-MDM2 interaction. Scaffold hopping was adopted via replacing the cis-imidazoline core of Nutlin-2 with a pyrazoline core, and molecular docking confirmed the binding orientation of the designed compounds at the p53-MDM2 interaction site.
View Article and Find Full Text PDFReduction of lymphotoxin beta receptor induces cellular senescence via the MDMX-p53 pathway.
Cell Death Discov
August 2025
Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.
The lymphotoxin β receptor (LTβR), a key activator of non-canonical NF-κB signaling, is expressed in various cells, including cancer cells. Although high expression of LTβR has been associated with poor patient prognosis and drug resistance, conflicting evidence suggested that LTβR induces apoptosis. To investigate the functional role of LTβR in tumors, we performed LTβR knockdown in cancer cells.
View Article and Find Full Text PDFA Dual-Specificity d-Peptide Antagonist of MDM2 and MDMX for Antitumor Immunotherapy.
J Med Chem
August 2025
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Designing metabolically stable peptides to target interactions of the tumor suppressor protein p53 with the two oncogenic proteins MDM2 and MDMX represents an attractive approach to harvesting "high-hanging fruits" often inaccessible to traditional anticancer drug discovery and development efforts. Here, we report the design of a proteolysis-resistant d-dodecapeptide, termed PMI-ω (EFWYVEFEKLLR), capable of disrupting the p53-MDM2/MDMX complex by antagonizing MDM2 and MDMX. PMI-ω, upon fabrication on gold nanoparticles, efficiently traversed tumor cells and killed them by reactivating the p53 signaling pathway.
View Article and Find Full Text PDFPolyethylene glycol incorporation to reduce the cytotoxicity associated with cationic cell-penetrating-peptide conjugation.
RSC Med Chem
August 2025
Department of Cell Signalling, Graduate School of Pharmaceutical Sciences, Nagoya City University Nagoya Aichi Japan.
Cell-penetrating peptides (CPPs) facilitate the intracellular delivery of cargo molecules. However, they can induce cytotoxicity when conjugated with certain bioactive peptides. We incorporated a branched polyethylene glycol unit to effectively minimize their nonspecific toxicity while preserving their essential biological functions, such as the inhibition of the p53/MDM2 interaction.
View Article and Find Full Text PDF